Monoclonal antibodies against TNF-α and IL-6, which are newer treatments for chronic autoimmune disorders, have been shown to be effective in the management of AA amyloidosis.[15] Nevertheless, novel therapeutic strategies targeting the formation of amyloid fibrils and amyloid deposition may generate new expectations for patients with AA amyloidosis.[9]. Here, IL6 is linked to AA amyloidosis.